Beijing Tiantan Biological

Beijing Tiantan Biological is a leading Chinese biopharmaceutical company specializing in the research, development, production, and sale of plasma-derived medicinal products. As a core subsidiary of China National Biotec Group (CNBG) under Sinopharm, the company operates one of the largest plasma collection and processing networks in China. Its product portfolio includes human albumin, intravenous and intramuscular immunoglobulins, and various coagulation factors such as Factor VIII and Factor IX. Following a major asset restructuring in 2017, the company focused its operations entirely on the blood products sector, divesting its vaccine business to its parent company. Beijing Tiantan Biological is listed on the Shanghai Stock Exchange and maintains a dominant market position in the Chinese blood products industry. The company is also expanding into recombinant protein therapies to address unmet needs in hematology.